HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

351 Clinical Trials
Gynecologic Phase II Enrolling
nct/study# NCT04865887 / IIT-KHLEIF

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

Learn More
Gynecologic Phase II Enrolling
nct/study# NCT05548296 / ACR-368-201

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

Learn More
Genito-Urinary Phase II Enrolling
nct/study# NCT07011342 / SCOUT-IIT

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer after FOcal Gland Treatment

Learn More
Genito-Urinary N/A Enrolling
nct/study# N/A / RENAL-CANCER-DATABASE

Renal Cancer Database – Prospective Chart Review

Learn More
Genito-Urinary N/A Enrolling
nct/study# N/A / PROSTATECANCERDATABASE/IIT

Active Surveillance for Prostate Cancer-Data and Biological Specimen Collection Protocol

Learn More
Leukemia Phase III Enrolling
nct/study# NCT06578247 / AC220-168

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD (-) ACUTE MYELOID LEUKEMIA (QUANTUM-WT) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD (-) AML)

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.